DHI1
Product Specifications
Target
Chk, CDK, Wee1
Related Pathways
Cell Cycle/Checkpoint
Bioactivity
DHI1 is an anti-leukemia agent with high selectivity towards Jurkat (IC50= 21.83 μM) and HL-60 (IC50= 19.14 μM) leukemia cells, while exhibiting low toxicity to non-cancerous cells. It induces G2/M cell cycle arrest in both Jurkat and HL-60 leukemia cells and S phase arrest in HL-60 cells, significantly affecting cell cycle signaling molecules such as Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasiveness of Jurkat and HL-60 cells by disrupting the cytoskeletal actin filaments, making it useful for research on hematological malignancies.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6307382-01 0.1 mL
HMMR, CT (HMMR, IHABP, RHAMM, Hyaluronan mediated motility receptor, Intracellular hyaluronic acid-binding protein, Receptor for hyaluronan-mediated motility, CD168) (MaxLight 650)
Sign In for Pricing
View Details MBS6307382-02 5x 0.1 mL
HMMR, CT (HMMR, IHABP, RHAMM, Hyaluronan mediated motility receptor, Intracellular hyaluronic acid-binding protein, Receptor for hyaluronan-mediated motility, CD168) (MaxLight 650)
Sign In for Pricing
View Details 